Anne Kathrin Merbach

Anne Kathrin Merbach

Auto-generated profile, based on publicly available information

Anne Kathrin Merbach

Medical Faculty University of Heidelberg, NCT Comprehensive Cancer Center Heidelberg, Heidelberg University Hospital, Germany

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2026 in Blood
Verified
Journal Article
Open access
ECEnise Ceran
Enise Ceran
SJSonia Jaramillo
Sonia Jaramillo
AMAnne Kathrin Merbach
Anne Kathrin Merbach
CRChristian Rohde
Christian Rohde
MWMaxi Wass
Maxi Wass
CMCarsten Müller-Tidow
Carsten Müller-Tidow
Relapse after remission remains the primary cause of treatment failure in acute myeloid leukemia (AML), underscoring the need for strategies to eliminate residual leukemic cells. The bone marrow microenvironment, largely orchestrated by the CXCR4-CXCL12 axis, enables leukemia cell survival and chemoresistance by anchoring blasts in their protective bone marrow niche. Motixafortide, a selective CXCR4 antagonist, mobilizes leukemic cells and disrupts tumor-microenvironment interactions in preclinical models. In this randomized, double-blind, placebo-controlled phase II trial (NCT02502968; registered at ClinicalTrials.gov), 128 patients in first remission received high‑dose cytarabine (HiDAC) plus Motixafortide or placebo. Median relapse-free survival (RFS) did not substantially differ between groups: 10.3 months (95% CI, 8.0-12.0) for Motixafortide and 11.5 months (95% CI, 8.6-24.1) for placebo (log-rank p=0.98). But scMRD analysis, performed before consolidation, demonstrated heterogeneity of CXCR4 inhibition benefit: in the placebo group, higher CXCR4 expression was associated with increased relapse risk (p=0.02), whereas in the Motixafortide group, higher CXCR4 expression was linked to a reduced relapse rate (p=0.047). Exploratory analyses identified scMRD levels at which higher MRD burden was associated with inferior overall survival (OS). Taken together, combining functional MRD profiling with biomarker-driven patient selection, such as CXCR4 expression, may enable more precise and effective post-remission interventions in AML. This clinical trial is registered at EudraCT number: 2014-002702-21